Armed with new insights into the interactions between cancer and the immune system, research teams are developing novel treatments to harness the full potential of the body’s natural defenses.
We have achieved so much since the full human genome sequence was published for the first time, can you believe that was over fifteen years ago this month?
Researchers have mapped the genetic variants that increase the risk of depression, in a bid to understand why depression strikes some people and not others.
Doctors in Germany have for the first time, successfully treated twins in utero using a biotech drug, pointing to a new way to eliminate disease.
Less than half the patients diagnosed with cancer respond favourably to chemotherapy. Now, a new method for testing how patients will respond to various drugs could pave the way for more personalised treatment.
Researchers have been developing CRISPR gene editing as a potential therapeutic tool for years, but now they have turned their attention to using it in cancer diagnostics.
A team of scientists at GRAIL has announced progression towards the goal of a simple blood test being able to detect a small tumour growing in your body.
A group of Africa-based researchers has issued guidelines for the ethical handling of samples for genomic studies, in an effort to combat ‘helicopter’ research.
For the first time, a human mini brain has been implanted into the skull of mice and surprisingly has continued to grow.
A new study published in the journal Nature Biotechnology brings us closer to a complete genetic blueprint by using a nanotechnology-based sequencing technique.
French CAR-T specialist Cellectis didn’t have the best time in 2017, but it seems their luck is changing, having just closed a $164 million U.S. public offering.